Bradley Coppens Buys Shares of AdaptHealth Corp.

On June 24, 2026, insider Bradley Coppens purchased 18,999 shares of AdaptHealth Corp. (NasdaqCM: AHCO). This transaction adds to insider activity as several other insiders also acquired shares on the same day.

Other Institutional Activity in AdaptHealth Corp.

Several institutional investors have been active in AdaptHealth Corp. OEP Capital Advisors, L.P. increased its holdings by 2,494,518 shares, ending with 16,312,698 shares valued at approximately $194.1 million. BlackRock, Inc. added 247,939 shares, bringing its total to 15,939,953 shares worth about $189.7 million. Reinhart Partners, LLC. grew its position by 1,981,198 shares, resulting in 10,081,983 shares valued at around $120 million. Meanwhile, Deerfield Management Company, L.P. and SkyKnight Capital, L.P. maintained their positions with no change.

AdaptHealth Corp. Stock Up 77.7%

Shares of AdaptHealth Corp. traded near $10.18 on Saturday. The company, with a market cap of approximately $1.4 billion, has a forward P/E ratio of 8.75 and a beta of 1.463. Its stock has ranged from a 52-week low of $8.51 to a high of $13.43. The 50-day moving average is $10.99, while the 200-day moving average is $10.21. The company has a current ratio of 0.93 and a quick ratio of 0.61, with a debt-to-equity ratio of 132.1.

Recent Earnings

AdaptHealth Corp. reported revenue of $3.29 billion, showing a growth of 5.4%. However, the company is currently not profitable, with a net margin of -2.42% and a return on equity of -4.85%. The next earnings report is expected on August 4, 2026.

Insider Buying and Selling at AdaptHealth Corp.

Several insiders, including Bradley Coppens, David Solomon III, Theodore Lundberg, Terence Connors, Susan Weaver, and Gregory Belinfanti, each purchased 18,999 shares of AdaptHealth Corp. on June 24, 2026. These transactions were not made under a pre-planned trading arrangement.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on AdaptHealth Corp. On May 11, 2026, RBC Capital maintained a 'buy' rating with a price target of $15. Canaccord Genuity and UBS both reiterated their 'buy' ratings on May 6, 2026, with price targets of $16 and $14, respectively. The consensus among analysts is a 'buy' recommendation, with an average price target of $14 based on 8 opinions.

About AdaptHealth Corp.

AdaptHealth Corp., based in Conshohocken, Pennsylvania, provides home medical equipment and supplies across the United States. Operating in the healthcare sector, the company focuses on sleep health, respiratory health, diabetes health, and wellness at home. It offers a range of products from sleep therapy equipment to diabetes management devices. Led by CEO Suzanne M. Foster, the company services beneficiaries of Medicare, Medicaid, and commercial insurance payors.

Bottom Line

Bradley Coppens' recent purchase of AdaptHealth shares adds to the insider buying activity, which investors closely watch for potential signals about a company's future prospects. The stock's recent trading price and analyst ratings suggest interest in its potential, though it's important to remember that filings like these are backward-looking and may not reflect current positions.